The NephroDI team joined our colleagues at the Rare & Genetic Kidney Drug Disease Drug Development Summit in Boston this week. We are coming back informed by discussion around new nephrology and renal treatment data, clinical trial successes, and regulatory best practices. Thanks to the organizers and attendees for a valuable summit filled with great content on patient input & participation, relevant examples & lessons learned, and a diverse and collaborative room of stakeholders.
Innovation & Patient Champion | Life Science, Biotech, & Pharma Advisor | Working Parent | DEI, STEM, Entrepreneurship, & Sustainability Advocate
The past three days have been filled with collaborative discussion and community building at the Rare & Genetic Kidney Disease Drug Development Summit. Special kudos to the conference organizers for inclusion of a lot of great content on incorporating patient voice and participation. We closed out the conference with an informative discussion between André Weinstock (Alport Syndrome Foundation), Joshua Tarnoff (NephCure), and David Feldman (National Kidney Foundation). These three patient advocates discussed building trust and sharing insights between patients and drug developers. It is inspiring to see this small but growing community bring a larger and diversifying list of potential treatments into clinical trials for rare disease kidney patients!